The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 13, 2021
Filed:
May. 02, 2017
Applicants:
The Scripps Research Institute, La Jolla, CA (US);
Zebra Biologies, Inc., Concord, MA (US);
Inventors:
Richard A. Lerner, La Jolla, CA (US);
Ronald M. Lindsay, Concord, MA (US);
Jia Xie, San Diego, CA (US);
Assignees:
The Scripps Research Institute, La Jolla, CA (US);
Zebra Biologies, Inc., Concord, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); G01N 33/53 (2006.01); C07K 16/28 (2006.01); C07K 16/24 (2006.01); A61P 27/06 (2006.01); A61P 27/02 (2006.01); A61P 27/00 (2006.01); A61P 25/02 (2006.01); A61P 25/28 (2006.01); A61K 9/00 (2006.01); C12N 15/85 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 9/0048 (2013.01); A61P 25/02 (2018.01); A61P 25/28 (2018.01); A61P 27/00 (2018.01); A61P 27/02 (2018.01); A61P 27/06 (2018.01); C07K 16/241 (2013.01); C07K 16/2878 (2013.01); C12N 15/85 (2013.01); A61K 39/395 (2013.01); A61K 39/39533 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/70 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01);
Abstract
The invention provides TrkB agonist antibodies or antigen-binding fragments that specifically enhance TrkB signaling activities. The invention also provides therapeutic methods of using such antibodies for promoting survival and regeneration of retinal ganglion cells, and for treating or preventing subjects suffering from or at risk of developing various neurodegenerative conditions such as glaucoma.